Article

Laser cataract surgery system receives patent

OptiMedica Corp. has received a patent for the Catalys Precision Laser System relating to the fundamental technology underlying laser cataract surgery.

 

Sunnyvale, CA-The U.S. Patent & Trademark Office (USPTO) has granted OptiMedica Corp. a patent relating to the fundamental technology underlying laser cataract surgery.

The patent for OptiMedica’s Catalys Precision Laser System describes a 3-D image-based femtosecond laser system for performing anterior capsulotomy and lens fragmentation during the cataract procedure.

“We are gratified to see the USPTO recognize the novelty of our invention and its practical realization in OptiMedica’s Catalys Precision Laser System,” said Mark Blumenkranz, MD, professor and chairman of the Department of Ophthalmology at Stanford University, OptiMedica board member, and one of the inventors of the technology. “Laser cataract surgery is an exciting new breakthrough in ophthalmology, and it has been an honor to be at the forefront of its advance.”

Daniel Palanker, PhD, of the Departments of Physics and Ophthalmology at Stanford University, is co-inventor of the system. It has been shown in numerous clinical studies to perform the laser cataract procedure with precision and accuracy. In addition, laser lens fragmentation with the system has been shown to reduce or eliminate the need for ultrasound energy to break up and remove the cataract.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
© 2025 MJH Life Sciences

All rights reserved.